← Back to all trials
Not Yet Recruiting
NCT07750717
Bedside Spirometry for Acute Lung Injury
Conditions: Respiratory Insufficiency
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 30
Sponsor: Centre Hospitalier Departemental Vendee
Location: Centre Hospitalier Universitaire de Nantes - Hôpital Hôtel Dieu Nantes
Summary
The diagnosis of Acute Respiratory Distress Syndrome (ARDS) is a syndromic diagnosis that groups together patients who may have very different prognoses and respond differently to the same therapies.
Additionally, non-invasive ventilation (NIV) has shown highly contrasting results in the early management of ARDS. One of the predictive criteria for NIV failure is an excessively high tidal volume during non-invasive ventilation.
SPIRALI is a pilot study evaluating the relevance of a respiratory physiology parameter, the tidal volume relative to the theoretical ideal body weigh, in the phenotypic classification of non-intubated ARDS patients. In this initial approach, the investigators will compare the tidal volume during high-flow oxygen therapy with the tidal volume obtained under NIV (after applying a settings optimization algorithm). The investigators hypothesize that if tidal volume is linked to each situation, the same patients will exhibit a high tidal volume both during spontaneous ventilation and under NIV.
Eligibility Criteria
Inclusion Criteria:
* Patient over 18 years of age;
* Patient hospitalized in intensive care for less than 24 hours;
* Patient with severe hypoxemic acute respiratory failure characterized by a PaO2/FiO2 ratio \< 300 mmHg and \> 150 mmHg under high-flow oxygen therapy at 60 L/min;
* Patient able to cooperate with the spirometry test;
* Patient able to follow the protocol and having given their informed written consent to participate in the study;
* Patient affiliated with the social security system or entitled to benefits;
Exclusion Criteria:
* Patients with an indication for intubation;
* Patients with a contraindication for or who refuse NIV;
* Patients with hemodynamic instability requiring vasopressor support greater than 0.25 μg/kg/min of norepinephrine;
* Patients with a Glasgow score \< 15;
* Patients with hypercapnia (PaCO2 \> 45 mmHg);
* Patients with a PaO2/FiO2 ratio \< 150 mmHg;
* Patients with cardiogenic pulmonary edema;
* Patients who have already undergone a session of NIV in intensive care during this stay;
* Patients with chronic respiratory failure (home oxygen therapy or home non-invasive ventilation (excluding indications solely for sleep apnea syndrome));
* Patients who have recently had a pneumothorax;
* Patients who have recently undergone eye surgery (e.g., cataract surgery) or throat surgery;
* Patients with significant arterial disease: recent heart attack, pulmonary embolism, poorly controlled hypertension despite treatment, etc.
* Patients already included in the study;
* Pregnant women, women in labor, or women who are breastfeeding;
* Patients under guardianship, conservatorship, or deprived of their liberty;
* Patients under an activated future protection mandate;
* Patients under family authorization;
* Patients under judicial protection;
Source: ClinicalTrials.gov (NCT07750717). StuddyBuddy aggregates publicly available trial information.